Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Neurodegenerative Disease Therapeutic Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CD100/SEMA4D drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CD100/SEMA4D ECD-Fc Fusion Protein High purity (>95%), Endotoxin controlled (<1 EU/µg). Sequence Verified. HEK293 expressed for native homodimerization and glycosylation. |
View SEMA4D Products |
| Gene Delivery | CD100/SEMA4D Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and cell-based functional assays. |
View SEMA4D Products |
| Benchmark Ab | Anti-CD100/SEMA4D Recombinant Antibody Biosimilar sequence based on Pepinemab (VX15/2503). For positive control and blocking validation. |
View SEMA4D Products |
| Validator | CD100/SEMA4D siRNA Set Target-specific knockdown pool for functional specificity validation in cell models. |
View SEMA4D Products |
| Related Target A | PLXNB1 (Plexin-B1) Primary high-affinity receptor mediating SEMA4D-induced cytoskeletal rearrangements and tumor cell migration. |
View PLXNB1 Products |
| Related Target B | CD72 Low-affinity immune receptor mediating SEMA4D-induced B-cell and dendritic cell activation. |
View CD72 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Native Homodimerization Requirement | HEK293-expressed ECD-Fc fusion naturally forms disulfide-linked homodimers essential for Plexin-B1 binding. |
| Receptor Specificity & Off-Target Screening | Highly purified PLXNB1, PLXNB2, and CD72 recombinant proteins available for cross-receptor screening. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included to validate blocking assays. |
| Phenotypic Validation False Positives | Sequence-verified siRNA sets included to confirm SEMA4D-dependence in functional assays. |
Live CD100/SEMA4D R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of CD100 (Semaphorin-4D, SEMA4D) has emerged as a key strategy in overcoming the immunosuppressive tumor microenvironment (TME) and treating neurodegenerative disorders. By blocking the interaction of SEMA4D with its high-affinity receptor Plexin-B1, novel therapeutics aim to prevent the exclusion of T-cells from the tumor core and inhibit neuroinflammatory cascades.
The race for CD100/SEMA4D therapeutics is intensifying, with major players shifting focus from traditional monotherapy mAbs to combination regimens with immune checkpoint inhibitors (PD-1/PD-L1) and specialized applications in neurodegeneration. As first-generation therapies reach late-stage clinical evaluation, the next wave of R&D is targeting bispecific modalities and optimization of tissue penetration.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibodies (mAbs) | Vaccinex, Inc. | NSCLC, HNSCC, Huntington's Disease | Blocking Assay (Requires native homodimeric SEMA4D ECD-Fc and Plexin-B1 target proteins) |
| Combination Therapies (mAb + CPI) | Merck, Bristol Myers Squibb | Advanced Solid Tumors | Synergy Profiling (Requires robust cellular validation using SEMA4D Lentivirus-transduced lines) |
| Bispecific Antibodies / Fusion Proteins | Biotech Innovators | Immunologically "Cold" Tumors | Dual-Targeting Validation (Requires high-purity SEMA4D and co-target antigens) |